KIAA0753 Inhibitors
Chemical inhibitors of KIAA0753 can impact its function in a variety of ways, primarily through the disruption of cellular pathways that are imperative for its role in centrosome duplication and spindle assembly. Alsterpaullone, Roscovitine, and Olomoucine, all cyclin-dependent kinase (CDK) inhibitors, can interfere with cell cycle progression. Since KIAA0753 is associated with microtubule organization, which is a process tightly regulated by the cell cycle, the inhibition of CDKs by these chemicals can lead to an indirect inhibition of KIAA0753. This results from the prevention of necessary phosphorylation events that are crucial for the proper functioning of KIAA0753. Similarly, SP600125 and SB203580 target the JNK and p38 MAP kinase pathways, respectively, both of which are involved in the cell's response to stress and cell cycle regulation. The disruption of these pathways can lead to an altered cellular environment where KIAA0753's role is indirectly inhibited due to the lack of proper signaling for microtubule stabilization and cell cycle control.
In addition to targeting kinases involved in cell cycle control, chemicals such as LY294002 and Wortmannin inhibit PI3K, and Rapamycin targets mTOR, all of which are parts of signaling pathways that affect cell growth and proliferation. These inhibitors can, therefore, indirectly inhibit KIAA0753 by disrupting signals necessary for centrosome cohesion and microtubule dynamics, crucial processes for cell division in which KIAA0753 is known to play a part. MEK inhibitors like PD98059 and U0126 can also indirectly inhibit KIAA0753 by affecting the MAP kinase pathway, which is responsible for transmitting proliferation and differentiation signals. By inhibiting this pathway, the function of KIAA0753 in regulating centrosome and microtubule dynamics can be indirectly hindered. Further, Leflunomide disrupts pyrimidine synthesis which is essential for DNA replication, thus affecting the cell cycle and indirectly curbing the activity of KIAA0753 in centrosome duplication. Lastly, Bortezomib, a proteasome inhibitor, can interfere with the degradation of proteins that regulate centrosome and spindle assembly, potentially leading to an accumulation or misregulation of proteins that would normally be involved in processes where KIAA0753 is essential, thereby indirectly inhibiting its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases which are a part of the cell cycle regulation pathways. KIAA0753 is known to associate with centrosomal and spindle microtubule organization. Inhibition of CDKs can disrupt cell cycle progression, thereby indirectly inhibiting the function of KIAA0753 in microtubule organization. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine targets CDKs involved in cell cycle control, which may indirectly affect KIAA0753's role in centrosome duplication and spindle assembly by disturbing the cell cycle-dependent phosphorylation events, leading to functional inhibition of KIAA0753. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Like other CDK inhibitors, Olomoucine can impede the cell cycle progression by inhibiting CDKs, potentially leading to an indirect inhibition of KIAA0753 by preventing necessary phosphorylation for centrosome and spindle function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can disrupt the JNK signaling pathway. As the JNK pathway is involved in cellular stress responses, inhibiting this pathway can indirectly impact KIAA0753's role in cell cycle regulation and response to stress. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which is involved in cell cycle regulation and stress response. The inhibition of p38 MAP kinase can indirectly affect KIAA0753's functionality in microtubule organization by altering the cell's response to stress signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt the PI3K/AKT pathway, which is involved in cell survival and metabolism. By inhibiting this pathway, LY294002 may indirectly affect KIAA0753's role in centrosome cohesion and microtubule stabilization. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K, leading to downstream effects on AKT signaling. This inhibition can indirectly disrupt processes where KIAA0753 is involved, particularly in the regulation of microtubule organization, by disturbing signaling pathways required for cell division. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which influences cell growth and proliferation. Since KIAA0753 is involved in centrosome and spindle function, disruption of mTOR signaling can indirectly inhibit the functional activity of KIAA0753 by affecting cellular growth processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAP kinase pathway. Inhibiting MEK and subsequently ERK1/2 can lead to an indirect inhibition of KIAA0753 by affecting the pathways involved in cell cycle control and centrosome function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also targets MEK, potentially leading to an indirect inhibition of KIAA0753 by impeding the cell’s ability to properly regulate the centrosome cycle and microtubule dynamics through disrupted MAP kinase signaling. | ||||||